Mylan to merge with Pfizer's Upjohn, creating generics giant

29 July 2019
generic_big

A generics powerhouse worth some $20 billion in revenues is to be created by the merger of Netherlands-incorporated Mylan (Nasdaq: MYL) and the off-patent business of New York-based pharma giant Pfizer (NYSE: PFE).

Pfizer’s Upjohn unit, which promotes aging thoroughbreds such as Lipitor (atorvastatin) and Viagra (sildenafil), will complement Mylan’s portfolio of new generics and biosimilars.

The combined entity will enjoy an expanded global reach, with strong positions in China and other emerging markets, and will benefit from the synergy of Mylan’s R&D-focused pipeline, and Upjohn’s commercial and medical infrastructure.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics